What is the clinical evidence from this study?

Study design: Review. Population: Myxomatous mitral valve disease (MMVD) in dogs.

What question did this study set out to answer?

This overview aims to explore the role of oxidative stress in the progression of myxomatous mitral valve disease in asymptomatic dogs, specifically between stages B1 and B2.

May 18, 2026Bulletin of University of Agricultural Sciences and Veterinary Medicine Cluj-Napoca Veterinary Medicine0 citationsOpen Access

Oxidative Stress as a Key Factor in Early (B1-B2) Myxomatous Mitral Valve Disease Progression in Asymptomatic Dogs: An Overview

AVAna Maria VLASUniversity of Agricultural Sciences and Veterinary Medicine of Cluj-Napoca FLFlorin LECAVector (United States)VSVioleta-Elena SIMIONSpiru Haret University

Key Result

Oxidative stress is active during the earliest stages of myxomatous mitral valve disease (Stage B1) in dogs, acting as a potential initiating factor in molecular remodeling rather than a byproduct.

Key Points

This overview aims to explore the role of oxidative stress in the progression of myxomatous mitral valve disease in asymptomatic dogs, specifically between stages B1 and B2.
Narrative review of ISI-indexed literature from the past five years using key search terms.
Analysis of oxidative imbalance, antioxidant capacity, and lipid peroxidation in dogs at stage B1.
Examination of TGF-β/mTOR signaling pathways and proteomic changes.
Dogs in stage B1 exhibit reduced antioxidant capacity and increased lipid peroxidation.
Dysregulated TGF-β/mTOR signaling and inflammatory mediators drive early molecular remodeling.
Proteomic analyses reveal significant alterations in redox and immune-related proteins during early disease stages.

Structured PICO

Population

Asymptomatic dogs with early (Stage B1-B2) myxomatous mitral valve disease (MMVD)

Outcome

Role of oxidative stress in early MMVD progression

Oxidative stress may act as an initiating driver of early valvular remodeling in canine myxomatous mitral valve disease, highlighting its potential as an early biomarker and therapeutic target.

Limitations

Most reviewed studies have relatively small sample sizes and focus on single breeds or genetically predisposed populations.
The majority of studies employ cross-sectional or observational designs, limiting causal inference.
Methodological variability and lack of standardized biomarker panels complicate interpretation.
Therapeutic interventions targeting oxidative stress remain underexplored in asymptomatic dogs.

Abstract

Myxomatous mitral valve disease (MMVD) is the most prevalent cardiac disorder in geriatric dogs, with Stage B1 defined as asymptomatic valvular degeneration without atrial or ventricular remodeling. Although the EPIC trial reported a median of 15 months before congestive onset, the molecular mechanisms driving progression between Stages B1-B2 remain unclear. Previous studies have largely overlooked early-stage oxidative changes leaving a key gap in understanding disease initiation.This short communication, preceding a comprehensive review, explores wether oxidative stress acts as an initiating factor rather than a secondary factor in MMVD progression. A narrative review of ISI-indexed literature from the past five years was conducted using the search terms “MMVD”, “Oxidative stress”, “Stage B1” and “TGF- β“. indings indicate that dogs in stage B1 already exhibit oxidative imbalance, with reduced antioxidant capacity and increased lipid peroxidation. Dysregulated TGFβ/mTOR signaling and inflammatory mediators appear to drive early molecular remodeling, while proteomics evidence reveals stage specific alterations in redox and immune-related proteins. These results suggest that oxidative stress may be an active driver of early valvular remodeling highlighting it’s potential as an early biomarker and therapeutic target to slow or prevent MMVD progression altogether.

问 AI

Bookmark

View Full Paper